%0 Journal Article
%T Single agent anti PD-1 inhibitors in esophageal cancer¡ªa first step in a new therapeutic direction
%A Elaine M. Walsh
%A Ronan J. Kelly
%J SCIE-indexed Journal
%D 2018
%R 10.21037/jtd.2018.03.43
%X Esophageal squamous cell carcinomas and adenocarcinomas have proven to be inherently resistant to systemic treatments as a result of histological, molecular and etiological heterogeneity, with limited responses seen after first line therapy. The promise of immunotherapy in esophagogastric cancer has been suggested for a long time due to the recognized link between infection, chronic inflammation, and malignancy. The emerging clinical trial data is somewhat confusing but it appears that anti programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) monoclonal antibodies do demonstrate some efficacy in a minority of gastroesophageal cancer patients with metastatic disease but with less activity when compared to melanoma or lung cancer
%U http://jtd.amegroups.com/article/view/19949/html